Schroder Investment Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $72.6M | Buy |
163,898
+40,646
| +33% | +$19M | 0.06% | 236 |
|
|
2025
Q4 | $55.9M | Buy |
123,252
+1,665
| +1% | +$718K | 0.04% | 282 |
|
|
2025
Q3 | $48.1M | Sell |
121,587
-13,380
| -10% | -$5.59M | 0.04% | 313 |
|
|
2025
Q2 | $60.1M | Sell |
134,967
-14,420
| -10% | -$6.65M | 0.05% | 256 |
|
|
2025
Q1 | $73.6M | Sell |
149,387
-14,241
| -9% | -$6.64M | 0.07% | 204 |
|
|
2024
Q4 | $65.3M | Sell |
163,628
-42,151
| -20% | -$19.5M | 0.06% | 245 |
|
|
2024
Q3 | $95.3M | Sell |
205,779
-23,040
| -10% | -$11.1M | 0.1% | 180 |
|
|
2024
Q2 | $107M | Buy |
228,819
+20,531
| +10% | +$8.91M | 0.12% | 151 |
|
|
2024
Q1 | $87.1M | Sell |
208,288
-24,692
| -11% | -$10.4M | 0.1% | 181 |
|
|
2023
Q4 | $94.8M | Buy |
232,980
+39,712
| +21% | +$14.7M | 0.12% | 160 |
|
|
2023
Q3 | $67.2M | Sell |
193,268
-1,684
| -0.9% | -$589K | 0.1% | 197 |
|
|
2023
Q2 | $68.6M | Buy |
194,952
+16,657
| +9% | +$5.61M | 0.1% | 202 |
|
|
2023
Q1 | $56.2M | Sell |
178,295
-21,566
| -11% | -$6.47M | 0.08% | 245 |
|
|
2022
Q4 | $57.7M | Buy |
199,861
+90,908
| +83% | +$27.7M | 0.09% | 223 |
|
|
2022
Q3 | $31.5M | Buy |
108,953
+54,563
| +100% | +$15.7M | 0.05% | 338 |
|
|
2022
Q2 | $15.2M | Sell |
54,390
-6,863
| -11% | -$1.84M | 0.02% | 541 |
|
|
2022
Q1 | $15.7M | Buy |
61,253
+15,359
| +33% | +$3.65M | 0.02% | 551 |
|
|
2021
Q4 | $10.1M | Sell |
45,894
-1,285
| -3% | -$250K | 0.01% | 611 |
|
|
2021
Q3 | $8.56M | Buy |
47,179
+2,891
| +7% | +$564K | 0.01% | 663 |
|
|
2021
Q2 | $8.93M | Buy |
44,288
+18,328
| +71% | +$3.83M | 0.01% | 705 |
|
|
2021
Q1 | $5.58M | Buy |
25,960
+401
| +2% | +$88.1K | 0.01% | 797 |
|
|
2020
Q4 | $6.04M | Sell |
25,559
-1,493
| -6% | -$343K | 0.01% | 761 |
|
|
2020
Q3 | $7.05M | Sell |
27,052
-54,791
| -67% | -$15.1M | 0.01% | 659 |
|
|
2020
Q2 | $23.8M | Buy |
81,843
+71,250
| +673% | +$19.3M | 0.04% | 381 |
|
|
2020
Q1 | $2.7M | Sell |
10,593
-1,456
| -12% | -$334K | 0.01% | 762 |
|
|
2019
Q4 | $2.64M | Sell |
12,049
-38,880
| -76% | -$7.87M | ﹤0.01% | 841 |
|
|
2019
Q3 | $8.49M | Buy |
50,929
+46,382
| +1,020% | +$8.21M | 0.02% | 656 |
|
|
2019
Q2 | $834K | Sell |
4,547
-29,775
| -87% | -$5.21M | ﹤0.01% | 937 |
|
|
2019
Q1 | $6.31M | Sell |
34,322
-51
| -0.1% | -$9.42K | 0.01% | 656 |
|
|
2018
Q4 | $5.7K | Buy |
34,373
+738
| +2% | +$128K | 0.01% | 654 |
|
|
2018
Q3 | $6.48M | Buy |
33,635
+6,326
| +23% | +$1.13M | 0.01% | 664 |
|
|
2018
Q2 | $4.03M | Buy |
27,309
+1,849
| +7% | +$287K | 0.01% | 748 |
|
|
2018
Q1 | $4.15M | Buy |
25,460
+1,300
| +5% | +$212K | 0.01% | 756 |
|
|
2017
Q4 | $3.62M | Hold |
24,160
| – | – | 0.01% | 823 |
|
|
2017
Q3 | $3.62M | Sell |
24,160
-9,238
| -28% | -$1.39M | 0.01% | 808 |
|
|
2017
Q2 | $4.25M | Buy |
33,398
+2,478
| +8% | +$298K | 0.01% | 753 |
|
|
2017
Q1 | $3.32M | Buy |
+30,920
| New | +$2.72M | 0.01% | 777 |
|
|
2016
Q3 | – | Sell |
-5,677
| Closed | -$488K | – | 1204 |
|
|
2016
Q2 | $488K | Sell |
5,677
-5,900
| -51% | -$510K | ﹤0.01% | 971 |
|
|
2016
Q1 | $908K | Sell |
11,577
-7,800
| -40% | -$706K | ﹤0.01% | 924 |
|
|
2015
Q4 | $2.44M | Sell |
19,377
-17,600
| -48% | -$2.12M | 0.01% | 847 |
|
|
2015
Q3 | $3.85M | Buy |
36,977
+25,400
| +219% | +$3.26M | 0.01% | 778 |
|
|
2015
Q2 | $1.41M | Hold |
11,577
| – | – | ﹤0.01% | 874 |
|
|
2015
Q1 | $1.39M | Buy |
+11,577
| New | +$1.39M | ﹤0.01% | 895 |
|
|
2013
Q4 | – | Sell |
-9,110
| Closed | -$691K | – | 1570 |
|
|
2013
Q3 | $691K | Hold |
9,110
| – | – | ﹤0.01% | 1060 |
|
|
2013
Q2 | $729K | Buy |
+9,110
| New | +$671K | ﹤0.01% | 1052 |
|
Other funds holding VRTX
VCM
VPM
Schroder Investment Management Group's VRTX Position: Q1 2026 in Review
Schroder Investment Management Group increased its Vertex Pharmaceuticals (VRTX) stake by 33% in Q1 2026, buying an estimated $19M and bringing the position to 163,898 shares worth $72.6M. The position accounts for 0.06% of the portfolio, ranked #236.
Schroder Investment Management Group first reported a position in VRTX in Q2 2013 and has held it in 45 quarters since. The position peaked at $107M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Schroder Investment Management Group held 163,898 shares of Vertex Pharmaceuticals worth $72.6M as of Q1 2026.
- Schroder Investment Management Group bought 40,646 Vertex Pharmaceuticals shares in Q1 2026, an estimated $19M.
- Vertex Pharmaceuticals made up 0.06% of Schroder Investment Management Group's portfolio in Q1 2026, its #236 holding.
- Schroder Investment Management Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Schroder Investment Management Group's Vertex Pharmaceuticals position peaked at $107M in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.